Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unsealed US Price-Fixing Complaint Reveals ‘Diary Of Collusion’

Excerpts From Notebook Detailing Alleged Anti-Competitive Conduct Published

Executive Summary

Fresh details have been revealed in the ongoing saga of US generic price-fixing litigation, with a newly-published unredacted complaint disclosing excerpts from a notebook alleged to contain details of anti-competitive conduct.

You may also be interested in...



UK Vaccines Business Pushes Wockhardt To Sales Growth

Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw another burst of sales in the UK, amid its tie-up with AstraZeneca for the COVID-19 vaccine.

Teva State Settlement On Price-Fixing Could Be First Of Many

Teva has struck a $950,000 deal to settle US price-fixing litigation with the state of Mississippi, in what the firm anticipates could be the first of multiple settlements with individual US states.

Subtracting Rx Adds To Perrigo OTC Pipeline

In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB150650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel